ALLIANCE |
DPI expands Pfizer deal Discovery Partners International has signed a multiyear chemistry deal with Pfizer that replaces and expands a two-year-old agreement. Under the new pact, DPI will deliver pharmaceutically relevant compounds for Pfizer's exclusive use. DPI says it will provide a broader range of compounds than in the past and that it will also deliver follow-up compound libraries for drug lead optimization. DPI had $48 million in sales to Pfizer between 2002 and 2003, more than half its total sales. It expects sales under the renewed contract of at least $43 million over the next two years. DPI competitor ChemBridge also recently renewed its contract with Pfizer (C&EN, Feb. 16, page 16). |
Want more information ? Interested in the hidden information ? Click here and do your request. |